NEA Management Company, LLC
CIK 1512848
13F filing for Q2 2026・No. 1,922
- Holdings
- US$1.59B
- Quarter change
- −US$171.22M
- Entries
- 26
- Net bought (estimate)
- −US$404.55M
The quarter change is the holdings' value against the quarter before, price moves included — not what was bought or sold; each institution's page estimates that.
Net bought (estimate)
Each stock's change in shares at the quarter-end price, added up: a new position counts as bought, one sold out as sold, shares held long only. Splits are compared split-adjusted; corporate actions under a new CUSIP are not estimated. An estimate from the filings, not actual trades.
- New 1
- Sold out 1
- Cut 2
- Added 0
- Corporate actions 0
- Unchanged 23
Largest holdings
26 stocks worth US$1.59B, options and bonds left out.
| Stock | This quarter | Shares | Value | Weight |
|---|---|---|---|---|
| Trevi Therapeutics, Inc.COM | Unchanged | 13,222,228 | US$246.59M | 15.53% |
| MBX Biosciences, Inc.COM | Unchanged | 3,614,486 | US$199.52M | 12.56% |
| GLUEMonte Rosa Therapeutics, Inc.COM | Unchanged | 7,692,298 | US$186.15M | 11.72% |
| Celcuity Inc.COM | Cut | 1,710,561 | US$178.96M | 11.27% |
| Spyglass Pharma, Inc.COM SHS | Unchanged | 7,392,301 | US$164.55M | 10.36% |
| Savara, Inc.COM | Unchanged | 24,471,264 | US$150.74M | 9.49% |
| Zenas BioPharma, Inc.COM | Unchanged | 4,023,219 | US$102.11M | 6.43% |
| COURCoursera, Inc.COM | Unchanged | 12,867,769 | US$72.57M | 4.57% |
| Aurinia Pharmaceuticals, Inc.COM | Unchanged | 3,969,834 | US$67.37M | 4.24% |
| CRSPCRISPR Therapeutics AGNAMEN AKT | Unchanged | 1,058,570 | US$57.73M | 3.64% |
Sign in (free) to see its 26 largest holdings and its trades. Sign in
Filings
The quarter's original 13F filings (SEC).
- 13F-HRFiled August 14, 2026SEC ↗
13F covers long positions in US-listed securities only; the data is SEC's, filed within 45 days of the quarter's end.